Pricing Log in Create free account
Friday 6 November 2026 Export TFX’s income statement to Excel — free account

Teleflex Incorporated

TFX Healthcare Medical Instruments & Supplies

Teleflex Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 17.2% from fiscal 2024.

Revenue
+28.9%
EPS
−17.3%
Free cash flow
+220.1%
Total debt
+47.7%

Quarter to June 2026, against a year earlier

152.16 2.29 +1.53%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
37.4×
Dividend yield
0.89%
F-score
5/9
Altman Z
2.04
Beneish M
−2.21
Dividend safety
20/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teleflex Incorporated 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 11:53 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 28 added · 14 removed · 43 modified; 4 with only figures updated

  1. Modified · Recent Strategic Actions

    In February 2025, we announced our intention to undertake a strategic transformation of the organization. In accordance with this strategy, on December 9, 2025, we announced that we entered into definitive agreements, which were approved at such time by our Board of Directors, to sell our Acute Care and Interventional Urology (also referred to as "IU") businesses to Intersurgical® Ltd and our OEM business to Montagu and Kohlberg (collectively referred to as the "Strategic Divestitures"). The combined total consideration from the Strategic Divestitures is $2.0 billion in cash, consisting of expected proceeds of $1.5 billion for our OEM business and $530 million for our Acute Care and IU businesses.